From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles.

Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals containing at least one oxygen heterocycle. Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five. The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-containing heterocycles. For each section, all oxygen heterocycle-containing drugs are presented along with a brief discussion about structural and drug application patterns.

[1]  Sohita Dhillon,et al.  Lapatinib , 2020, Reactions Weekly.

[2]  Cheng‐He Zhou,et al.  Recent advance in oxazole-based medicinal chemistry. , 2018, European journal of medicinal chemistry.

[3]  Ana-Marija Cikoš,et al.  16-membered macrolide antibiotics: a review. , 2017, International journal of antimicrobial agents.

[4]  Jean-Denis Docquier,et al.  An update on β-lactamase inhibitor discovery and development. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  I. Jacobson,et al.  Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C , 2017, Expert review of gastroenterology & hepatology.

[6]  Fernanda Borges,et al.  Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. , 2017, Journal of medicinal chemistry.

[7]  P. Richardson,et al.  Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  David R Corey,et al.  Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy , 2017, Nature Neuroscience.

[9]  D. Yellon,et al.  Anthracycline Chemotherapy and Cardiotoxicity , 2017, Cardiovascular Drugs and Therapy.

[10]  P. Murumkar,et al.  Medicinal Chemistry Perspective of Fused Isoxazole Derivatives. , 2016, Current topics in medicinal chemistry.

[11]  L. Low,et al.  Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia , 2016, Front. Med..

[12]  A. Letai,et al.  The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. , 2016, Blood.

[13]  K. Jarnagin,et al.  Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. , 2016, Immunotherapy.

[14]  W. Paulus,et al.  D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review , 2015, The international journal of neuropsychopharmacology.

[15]  R. Bergquist,et al.  Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty , 2015, Infectious Diseases of Poverty.

[16]  B. Elewski,et al.  Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. , 2015, Journal of the American Academy of Dermatology.

[17]  Reshma J. Nevagi,et al.  Biological and medicinal significance of benzofuran. , 2015, European journal of medicinal chemistry.

[18]  Christine Roder,et al.  Auranofin: Repurposing an Old Drug for a Golden New Age , 2015, Drugs in R&D.

[19]  J. Karlowsky,et al.  Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection , 2015, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[20]  J. T. Njardarson,et al.  Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. , 2014, Journal of medicinal chemistry.

[21]  J. T. Njardarson,et al.  Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery. , 2014, Journal of medicinal chemistry.

[22]  C. Eleazu,et al.  Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans , 2013, Journal of Diabetes & Metabolic Disorders.

[23]  N. Ford,et al.  Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic Review and Meta-Analysis of Randomized Trials , 2013, PloS one.

[24]  C. Melián,et al.  Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily. , 2013, Journal of veterinary internal medicine.

[25]  S. Parthasarathy,et al.  Sugammadex: A revolutionary drug in neuromuscular pharmacology , 2013, Anesthesia, essays and researches.

[26]  S. Crooke,et al.  Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B , 2013, British journal of clinical pharmacology.

[27]  L. Buckley,et al.  Anticoagulants: A Review of the Pharmacology, Dosing, and Complications , 2013, Current Emergency and Hospital Medicine Reports.

[28]  C. Crews,et al.  From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. , 2013, Natural product reports.

[29]  L. Peterson Reactive metabolites in the biotransformation of molecules containing a furan ring. , 2013, Chemical research in toxicology.

[30]  B. Seto Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer , 2012, Clinical and Translational Medicine.

[31]  Z. Espinel,et al.  Treatment of nightmares with prazosin: a systematic review. , 2012, Mayo Clinic proceedings.

[32]  G. Karakiulakis,et al.  Hyaluronic acid: A key molecule in skin aging , 2012, Dermato-endocrinology.

[33]  A. McBride,et al.  Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[34]  Xiao Zhai,et al.  Lactulose: an effective preventive and therapeutic option for ischemic stroke by production of hydrogen , 2012, Medical gas research.

[35]  Jonas Boström,et al.  Oxadiazoles in medicinal chemistry. , 2012, Journal of medicinal chemistry.

[36]  C. Perry,et al.  Pentosan Polysulfate , 2012, Drugs.

[37]  R. Raz Fosfomycin: an old--new antibiotic. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[38]  David D. Anderson,et al.  Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors. , 2011, Future medicinal chemistry.

[39]  Nicholas H Oberlies,et al.  Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma , 2011, The Journal of Antibiotics.

[40]  S. Ōmura,et al.  Ivermectin, ‘Wonder drug’ from Japan: the human use perspective , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[41]  Nicholas A. McGrath,et al.  A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives , 2010 .

[42]  Wolfgang Dekant,et al.  Hepatobiliary Toxicity of Furan: Identification of Furan Metabolites in Bile of Male F344/N Rats , 2010, Drug Metabolism and Disposition.

[43]  A. Paci,et al.  Oxazaphosphorines: new therapeutic strategies for an old class of drugs , 2010, Expert opinion on drug metabolism & toxicology.

[44]  Franz Schuler,et al.  Oxetanes in drug discovery: structural and synthetic insights. , 2010, Journal of medicinal chemistry.

[45]  S. Nair,et al.  Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.

[46]  D. Hughes,et al.  Structure and mechanism of the lincosamide antibiotic adenylyltransferase LinB. , 2009, Structure.

[47]  P. Hunter Not boring at all , 2009, EMBO reports.

[48]  W. Greenlee,et al.  Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. , 2008, Journal of medicinal chemistry.

[49]  M. Georgiadis,et al.  Crystal structure of DNA-bound Co(III)·bleomycin B2: Insights on intercalation and minor groove binding , 2008, Proceedings of the National Academy of Sciences.

[50]  D. Snyder,et al.  Preliminary studies on the effectiveness of the novel pulicide, spinosad, for the treatment and control of fleas on dogs. , 2007, Veterinary parasitology.

[51]  T. Hermann,et al.  Aminoglycoside antibiotics: old drugs and new therapeutic approaches , 2007, Cellular and Molecular Life Sciences.

[52]  Arun K. Ghosh,et al.  Bis‐Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance , 2006, ChemMedChem.

[53]  C. Sánchez The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. , 2006, Basic & clinical pharmacology & toxicology.

[54]  L. Dunkel Use of aromatase inhibitors to increase final height , 2006, Molecular and Cellular Endocrinology.

[55]  Nuggehally R Srinivas,et al.  Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. , 2006, Biomedical chromatography : BMC.

[56]  P. Yogeeswari,et al.  Camptothecin and its analogues: a review on their chemotherapeutic potential , 2005, Natural product research.

[57]  F. Rutjes,et al.  2-Deoxystreptamine: central scaffold of aminoglycoside antibiotics. , 2005, Chemical reviews.

[58]  R. Zuwallack,et al.  Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease , 2004, Expert opinion on pharmacotherapy.

[59]  B. Bozdoğan,et al.  Oxazolidinones: activity, mode of action, and mechanism of resistance. , 2004, International journal of antimicrobial agents.

[60]  T. Raghavendra Neuromuscular Blocking Drugs: Discovery and Development , 2002, Journal of the Royal Society of Medicine.

[61]  H. Yasuda,et al.  Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren’s Syndrome , 2002, Clinical drug investigation.

[62]  F. Guéritte General and recent aspects of the chemistry and structure-activity relationships of taxoids. , 2001, Current pharmaceutical design.

[63]  K. Antman,et al.  Introduction: the history of arsenic trioxide in cancer therapy. , 2001, The oncologist.

[64]  K. Goa,et al.  Galantamine: a review of its use in Alzheimer's disease. , 2000, Drugs.

[65]  R. Abraham,et al.  Immunopharmacology of rapamycin. , 1996, Annual review of immunology.

[66]  R. N. Brogden,et al.  Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. , 1994, Drugs.

[67]  P. Hadváry,et al.  The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. , 1991, The Journal of biological chemistry.

[68]  C. A. Nugent,et al.  Guanadrel Sulfate: A Postganglionic Sympathetic Inhibitor for the Treatment of Mild to Moderate Hypertension , 1983, Pharmacotherapy.

[69]  S. Ōmura,et al.  Mechanism of action of cerulenin on fatty acid synthetase. Effect of cerulenin on iodoacetamide-induced malonyl-CoA decarboxylase activity. , 1982, Journal of biochemistry.

[70]  P. Corvol,et al.  Importance of the lactonic ring in the activity of steroidal antialdosterones. , 1980, Biochemical pharmacology.